Gilles Avenard, MD – CEO & Chairman of the Board
Board member or advisor for several biotech companies ; co-founder and COO of BioAlliance Pharma SA – ONXEO (NYSE EURONEXT) until 2010. Gilles Avenard was involved in the development of several innovative medicines until their registration in Europe and the USA. Before that, he was Projects Director for Hoechst Marion Roussel (Sanofi) and Medical Director of Bio-Transfusion (LFB).
Philippe Billiald, PharmD, PhD – Censor
Professor at Paris-Sud University ; Antibody Scientific Consultant and President of the Strategic Comity. Expert in the field of therapeutic and diagnostic antibody engineering, Philippe Billiald is the author of two patents and close to 40 papers in peer-reviewed scientific journals, books and scientific magazines.
Catherine Boule – CapDecisif Management
Partner at CapDecisif Management, Catherine Boule holds a Master of Science in Molecular Biology from the University Paris VI and a degree in “Management of Technological Innovation in Bio-Industries ” from the INA Paris-Grignon / Reims Management School. She worked at the Curie Institute (CNRS) in Paris before working with innovative biotechnology start-ups for an incubator in the Paris region.
Jean Pierre Cazenave, MD – Director
Honorary Professor of Hematology and Transfusion (University of Strasbourg), President of ARMESA, a Strasbourg medical research Association and member of the French Académie Nationale de Médecine. After his MD degree (1970, University of Strasbourg), he moved to Canada at Mac Master University, Ontario, where he worked on platelet physiology and pharmacology for a PhD and was appointed Assistant Professor of Pathology. Back to Strasbourg Blood Transfusion Center (1978) to create an INSERM research unit (U311) in 1986 devoted to the Biology and Pharmacology of Hemostasis and Thrombosis. From 1987 to 2013, he has been the Director of the Blood Transfusion Center of EFS-Alsace in Strasbourg. He is a past president (1992-1995) and vice- president (2002-2010) of the Société Française de Transfusion Sanguine. He is member of several international medical societies, and author of more than 600 scientific publications.
Joachim Dupont – Director
Joachim Dupont graduated from Paris Dauphine University and began his career in risk management at Axa Corporate Solutions before joining Lazard Frère Gestion. In 2012, he co-founded Anaxago, an investment company and is now an administrator of more than 20 young innovative companies. ANAXAGO has become in few years the market leader in equity crowdfunding by offering a new form of investment and an alternative financing for innovative companies and real estate professionals. Anaxago has financed more than one hundred companies for more than € 50 million since 2012 thanks to a community of 5000 private investors. Since 2014 the company has been approved as a Participating Investment Advisor.
Martine Jandrot-Perrus, MD, PhD – Director
Research Director (DR1) at Inserm (UMR_S1148 Inserm Paris-Diderot University) ; Thrombosis Scientific Consultant. Internationally recognized expert of thrombosis and entitled with an Hospital Research contract in translational research with the AP-HP ; Martine Jandrot-Perrus is the author of 102 papers in international scientific journals and of 4 patents.
Christophe Pasik, MD – Director
Christophe is the co Founder (in 2006) and current CEO of Keocyt SAS a French pharmaceutical company. He is an active Business Angel, co founder of several healthcare societies and Board member of French Biotech and Healthcare companies. Prior to that and since 1990, he held various positions in Pharma companies such as Pfizer, Pharmacia, Catalent and Merck Lipha in France and abroad.